{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:51:55Z","timestamp":1786978315006,"version":"build-2736575974"},"reference-count":56,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T00:00:00Z","timestamp":1511395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>\n                    Delafloxacin is a new fluoroquinolone antimicrobial approved for the treatment of acute bacterial skin and skin structure infections (\n                    <jats:styled-content style=\"fixed-case\">ABSSSI<\/jats:styled-content>\n                    s) in adults using dosage regimens of 300\u00a0mg intravenously every 12\u00a0hours, 450\u00a0mg orally every 12\u00a0hours, or switching from intravenous to oral regimens for a 5\u2010 to 14\u2010day treatment duration. Dosage adjustments in patients with severe renal dysfunction (estimated glomerular filtration rate [\n                    <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>\n                    ]\u00a0=\u00a015\u201329\u00a0ml\/min\/1.73\u00a0m\n                    <jats:sup>2<\/jats:sup>\n                    ) are not required for oral doses but should be decreased to 200\u00a0mg intravenously every 12\u00a0hours in patients requiring parenteral therapy. Due to insufficient data, use of delafloxacin is not recommended for patients on hemodialysis or with end\u2010stage renal disease (\n                    <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>\n                    &lt;\u00a015\u00a0ml\/min\/1.73\u00a0m\n                    <jats:sup>2<\/jats:sup>\n                    ). Delafloxacin works through inhibition of\n                    <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>\n                    gyrase (topoisomerase\n                    <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>\n                    ) and topoisomerase\n                    <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content>\n                    , which are essential enzymes for bacterial\n                    <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>\n                    transcription, replication, repair, and recombination and exhibits bactericidal activity against gram\u2010positive and gram\u2010negative organisms through a concentration\u2010dependent matter. Delafloxacin has a very broad spectrum of activity against atypical, anaerobic, and resistant gram\u2010negative and gram\u2010positive bacteria, including methicillin\u2010resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    and\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    . During phase 3 trials, the most common side effects associated with delafloxacin were gastrointestinal (nausea, diarrhea). Unlike other fluoroquinolones, there does not seem to be a risk of\n                    <jats:styled-content style=\"fixed-case\">QT<\/jats:styled-content>\n                    c prolongation or phototoxicity with delafloxacin. The availability of both parenteral and oral formulations for delafloxacin distinguishes it from many of the currently available agents approved for\n                    <jats:styled-content style=\"fixed-case\">ABSSSI<\/jats:styled-content>\n                    s. Phase\n                    <jats:styled-content style=\"fixed-case\">3<\/jats:styled-content>\n                    studies for the treatment of respiratory infections are currently under way, and future results of these studies will further help delineate the role of delafloxacin.\n                  <\/jats:p>","DOI":"10.1002\/phar.2050","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T12:25:18Z","timestamp":1508761518000},"page":"108-121","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone"],"prefix":"10.1002","volume":"38","author":[{"given":"Jonathan C.","family":"Cho","sequence":"first","affiliation":[{"name":"College of Pharmacy The University of Texas at Tyler Tyler Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Crotty","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Methodist Dallas Medical Center Dallas Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Pharmacy OU Medical Center Oklahoma City Oklahoma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marylee V.","family":"Worley","sequence":"additional","affiliation":[{"name":"College of Pharmacy Nova Southeastern University Fort Lauderdale Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,23]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"issue":"6","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/163.6.1279","article-title":"Rapid development of ciprofloxacin resistance in methicillin\u2010susceptible and \u2010resistant Staphylococcus aureus","volume":"163","author":"Blumberg HM","year":"1991","journal-title":"J Infect Dis"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi5000564"},{"issue":"4","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"e02609","DOI":"10.1128\/AAC.02609-16","article-title":"In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller MA","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-10"},{"issue":"11","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.03482-14","article-title":"Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates","volume":"58","author":"Siala W","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-252"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks307"},{"issue":"10","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/AAC.00941-16","article-title":"In vitro activity of delafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis","volume":"60","author":"Flamm RK","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2016.08.012","article-title":"Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community\u2010acquired respiratory tract pathogens","volume":"48","author":"Thabit AK","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"e00772","DOI":"10.1128\/AAC.00772-17","article-title":"In vitro activity of delafloxacin and microbiological response against fluoroquinolone susceptible and non\u2010susceptible S. aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections (ABSSSI)","volume":"61","author":"McCurdy S","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1128\/AAC.47.9.3008-3011.2003","article-title":"In vitro activities of ABT\u2010492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis","volume":"47","author":"Goldstein EJ","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.283-286.2000"},{"issue":"2","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.juro.2015.01.094","article-title":"Effects of urine matrix and pH on the potency of delafloxacin and ciprofloxacin against urogenic Escherichia coli and Klebsiella pneumoniae","volume":"194","author":"So W","year":"2015","journal-title":"J Urol"},{"key":"e_1_2_12_17_1","unstructured":"Melinta Therapeutics Inc.Baxdela (delafloxacin) for injection tablet package insert.Lincolnshire IL;2017."},{"issue":"7","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1128\/AAC.48.7.2771-2777.2004","article-title":"In vitro and bactericidal activities of ABT\u2010492, a novel fluoroquinolone, against gram\u2010positive and gram\u2010negative organisms","volume":"48","author":"Almer LS","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.6.1867-1874.2003"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","unstructured":"HubandM StreitJ ShortridgeD FlammR.In vitro evaluation of delafloxacin activity when tested against contemporary ABSSSI isolates from Europe and surrounding areas (2014\u20132016): results from the SENTRY antimicrobial surveillance program [poster 1351]. Presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases. Vienna Austria April 22\u201325 2017.","DOI":"10.1093\/ofid\/ofx163.904"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","unstructured":"ShortridgeD StreitJ HubandMD RhombergP FlammR.In vitro evaluation of delafloxacin activity when tested against contemporary ABSSSI isolates from the United States (2014\u20132016): results from the SENTRY antimicrobial surveillance program. Presented at the ASM Microbe 2017. New Orleans LA USA June 4 2017.","DOI":"10.1093\/ofid\/ofx163.904"},{"issue":"6","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.00181-13","article-title":"A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms","volume":"57","author":"Bauer J","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/jac\/dkg363","article-title":"Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents","volume":"52","author":"Frean J","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1128\/AAC.47.10.3260-3269.2003","article-title":"In vitro antibacterial potency and spectrum of ABT\u2010492, a new fluoroquinolone","volume":"47","author":"Nilius AM","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/AAC.47.6.1875-1881.2003","article-title":"Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002","volume":"47","author":"Zhanel GG","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1179\/joc.2004.16.3.227","article-title":"In vitro activity of ABT\u2010492 against anaerobic bacteria","volume":"16","author":"Sillerstrom E","year":"2004","journal-title":"J Chemother"},{"issue":"1","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jac\/dkh304","article-title":"The in\u00a0vitro activity of a new fluoroquinolone, ABT\u2010492, against recent clinical isolates of Chlamydia pneumoniae","volume":"54","author":"Hammerschlag MR","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1128\/AAC.47.12.3973-3975.2003","article-title":"Comparative in\u00a0vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT\u2010492 and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"47","author":"Waites KB","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2014.04.007"},{"issue":"2","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3201\/eid0702.010239","article-title":"Emerging mechanisms of fluoroquinolone resistance","volume":"7","author":"Hooper DC","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.49.4.1633-1635.2005","article-title":"Mutant prevention concentrations of ABT\u2010492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens","volume":"49","author":"Hermsen ED","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/AAC.02798-15","article-title":"In vitro activity of aelafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance","volume":"60","author":"Soge OO","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262010-00002"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.817"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.669"},{"issue":"8","key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1128\/AAC.00647-16","article-title":"In vivo pharmacodynamic target assessment of delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model","volume":"60","author":"Lepak AJ","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_37_1","unstructured":"BortolonE MolstadD RemyJ MarraA DuffyE HooverR.In vivo PK\/PD of delafloxacin against Escherichia coli and Pseudomonas aeruginosa in the mouse thigh infection model [poster 349]. Presented at the ASM Microbe 2017. New Orleans LA USA June 1\u20135 2017."},{"issue":"5","key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijantimicag.2005.02.004","article-title":"Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in\u00a0vitro dynamic model","volume":"25","author":"Firsov AA","year":"2005","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.43.3.672","article-title":"Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in\u00a0vitro model of infection","volume":"43","author":"Lacy MK","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_2_12_41_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. October 2013. Available fromhttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071185.pdf. Accessed July 11 2017."},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.10.009"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv411"},{"key":"e_1_2_12_44_1","doi-asserted-by":"crossref","unstructured":"CammarataS GardovskisJ FarleyB et\u00a0al.Results of a global phase 3 study of delafloxacin (DLX) compared to vancomycin with aztreonam (VAN) in acute bacterial skin and skin structure infections (ABSSSI) [poster 776]. Presented at ID Week 2015. San Diego CA USA October 7\u201311 2015.","DOI":"10.1093\/ofid\/ofv133.493"},{"key":"e_1_2_12_45_1","unstructured":"O'RiordanW McManusA TerasJ et\u00a0al.A global phase 3 study of delafloxacin (DLX) compared to vancomycin\/aztreonam (VAN\/AZ) in patients with acute bacterial skin and skin structure infections (ABSSSI) [Poster 1347]. Presented at ID Week 2016. New Orleans LA USA October 26\u201330 2016."},{"key":"e_1_2_12_46_1","unstructured":"ShahS BayntonB LawrenceL QuintasM LiangS CammarataS.Delafloxacin (DLX) is effective and well\u2010tolerated in treatment of obese patients with acute bacterial skin and skin structure infections (ABSSSI) versus vancomycin\/aztreonam (VAN\/AZ) [poster 1354]. Presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases. Vienna Austria April 22\u201325 2017."},{"key":"e_1_2_12_47_1","unstructured":"BeasleyR OguchiG LiangS LawrenceL CammarataS.Delafloxacin (DLX) is effective and well\u2010tolerated in treatment of patients with renal impairment with acute bacterial skin and skin structure infections (ABSSSI) versus vancomycin\/aztreonam (VAN\/AZ) pPoster 1355]. Presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases. Vienna Austria April 22\u201325 2017."},{"key":"e_1_2_12_48_1","unstructured":"LongcorJ HopkinsS WiklerM BukofzerS LawrenceL.A Phase 2 study of the safety and efficacy of oral delafloxacin (DLX) in subjects with acute bacterial exacerbation of chronic bronchitis (ABECB) [poster 1071]. Presented at ID Week 2012. San Diego CA USA October 17\u201321 2012."},{"key":"e_1_2_12_49_1","unstructured":"LongcorJ HopkinsS WiklerM BukofzerS LawrenceL.A phase 2 study of the safety and efficacy of oral delafloxacin (DLX) in community acquired pneumonia (CAP) [poster 1069]. Presented at ID Week 2012. San Diego CA USA October 17\u201321 2012."},{"key":"e_1_2_12_50_1","unstructured":"Melinta Therapeutics Inc.A phase 3 multicenter randomized double\u2010blind comparator\u2010controlled study to evaluate the safety and efficacy of intravenous to oral delafloxacin in adult subjects with community\u2010acquired bacterial pneumonia. ClinicalTrials.gov.Bethesda MD:National Library of Medicine. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02679573. Accessed July 11 2017."},{"key":"e_1_2_12_51_1","unstructured":"Melinta Therapeutics Inc.A comparative evaluation of the single\u2010dose efficacy of oral delafloxacin versus the single\u2010dose efficacy of an intramuscular injection of ceftriaxone in subjects with uncomplicated urogenital gonorrhea. ClinicalTrials.gov.Bethesda MD:National Library of Medicine. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02015637. Accessed July 11 2017."},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04813-14"},{"key":"e_1_2_12_53_1","unstructured":"FergusonJ LawrenceL PaulsonS SchlosserMJ CammarataS.Assessment of phototoxicity potential of delafloxacin in healthy male and female subjects: a phase I study [poster 1198]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy 2015. San Diego CA USA September 17\u201321 2015."},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.11.019"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.10.016"},{"key":"e_1_2_12_56_1","unstructured":"FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Available fromhttps:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm511530.htm. Accessed July 9 2017."},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis346"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2050","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:49:18Z","timestamp":1761061758000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,23]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/phar.2050"],"URL":"https:\/\/doi.org\/10.1002\/phar.2050","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,23]]},"assertion":[{"value":"2017-11-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}